echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > BJH: allogeneic hematopoietic cell transplantation in patients with relapsed/refractory anaplastic large-cell lymphoma

    BJH: allogeneic hematopoietic cell transplantation in patients with relapsed/refractory anaplastic large-cell lymphoma

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Anaplastic large cell lymphoma (ALCL) is a T-cell/Zero cell line (NHL) of CD30+ invasive non-Hodgkin lymphoma (NHL), which accounts for 2%
    of all NHL in adults.


    Therefore, a research team used the observational database of the International Center for Blood and Bone Marrow Transplantation Research (CIBMTR) to assess the prognosis
    of allogeneic-HCT in patients with ALCL.


    Figure 1: Allogeneic hematopoietic cell transplant results
    for anaplastic large-cell lymphoma.


    Figure 2: Effect
    of disease status on transplant outcomes.


    About multivariate regression analysis of African American ethnicity (risk ratio [HR] 2.


    Overall, these data suggest that allo-HCT can achieve lasting disease control
    in a significant proportion of patients with R/R ALCL.


     

    Original Source:

    Furqan, F, Ahn, KW, Chen, Y, Kaur, M, Abutalib, SA, Ahmed, N, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.